The metabolic syndrome (MetS) comprises a cluster of metabolic abnormalities with insulin resistance and adiposity as its central features, 
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to increased cardiovascular risk in concert, they do not explain the increased propensity of vascular disease in subjects with MetS, and the precise mechanisms for this increased propensity remain to be elucidated. Inflammation is pivotal in all phases of atherosclerosis from foam cell formation to culmination in acute coronary syndromes.
Furthermore, several lines of evidence demonstrate that diabetes is a proinflammatory state. It appears that low-grade chronic inflammation is a central feature of MetS and could contribute to increased risk for both CVD and diabetes in MetS.
Inflammation and the Metabolic Syndrome
A large number of investigators have consistently reported that the MetS is associated with low-grade systemic inflammation.
Pro-inflammatory Cytokines and the Metabolic Syndrome
Cytokines, in particular interleukin (IL)-1, tumor necrosis factor (TNF), and IL-6, are the main inducers of the acute phase response (APR). Several lines of evidence indicate that IL-6 is the central mediator of the inflammatory response.
11-14 IL-6 has been shown to directly impair insulin signaling in mouse hepatocytes and 3T3 adipocytes via decreased activation of insulin receptor substrate 1 (IRS-1) and PI3 kinase as well as impaired insulininduced glycogenesis in liver cells. IL-6 knockout mice have an impaired inflammatory response. [11] [12] [13] [14] IL-1 and TNF can induce IL-6. IL-1 knockout mice do not develop appreciable IL-6 and also have a diminished inflammatory response. [11] [12] [13] [14] In addition, IL-6 subcutaneously administered to humans induces an acute inflammatory response. [11] [12] [13] [14] Two important acute-phase proteins, C-reactive protein (CRP) and fibrinogen, have IL-6 response elements in the promoter regions of their genes; the presence of IL-6, therefore, may facilitate the production of CRP and fibrinogen. In fact, IL-6 is believed to be the main driver of CRP release from hepatocytes. [11] [12] [13] [14] IL-6 plasma levels are significantly increased in murine and human insulin resistance and obesity and baseline IL-6 levels independently predict future cerebrovascular events (CVEs).
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Pickup et al. 15 have shown increased levels of IL-6 in subjects with more than two features of the MetS. Furthermore, we have also shown that in type 2 diabetes both CRP and monocyte release of IL-6 are significantly increased compared with patients without diabetes controls. 16 In a study on a group of 58 Pima Indians without diabetes, employing the hyperinsulinemic euglycemic clamp to assess insulin action, the results indicated that plasma IL-6 was positively related to adiposity and negatively related to insulin sensitivity. The investigators concluded that the relationship between IL-6 and insulin action appeared to be mediated through adiposity. Thus, IL-6 levels are closely related to features of the MetS.
IL-6 is an important adipocyte signaling molecule. 17 Adipose tissue IL-6 expression and circulating IL-6 concentrations are positively correlated with obesity, IGT, and insulin resistance. [11] [12] [13] [14] Both expression and circulating levels decrease with weight loss. Furthermore, plasma IL-6 concentrations predict the development of type 2 diabetes and CVD. It is released from visceral and subcutaneous fat subsequent to sympathetic nervous system (SNS) activation (e.g. with stress). Approximately 25-30% of systemic IL-6 is derived from adipose tissue. IL-6 and free fatty acid fluxes are the pathogenic transmitters of the effects of obesity, the latter, together with corticosteroids amplifying insulin resistance thereby playing a role in the pathogenesis of MetS.
TNF is another pro-inflammatory cytokine secreted by monocytemacrophages and endothelial cells, and also to a large extent by adipocytes. [18] [19] [20] [21] Several studies have shown that levels of TNF are an important regulator of insulin sensitivity and that neutralization of TNF improves insulin sensitivity in leptin-receptor-deficient Zucker (fa/fa) rats. In human subjects, TNF messenger RNA (mRNA) and protein positively correlate with body adiposity and decrease in obese subjects with weight loss; however, insulin sensitivity was not studied. [18] [19] [20] [21] Obesity is one of the major features of the MetS. Adipose tissue expression of TNF is increased in obese rodents and humans and is positively correlated with adiposity, and insulin resistance TNF levels also strongly correlate with the body mass index (BMI). [18] [19] [20] [21] TNF is overexpressed in adipose and muscle tissues of obese individuals compared with tissues from lean individuals. [18] [19] [20] [21] IL-10 is a potent anti-inflammatory cytokine. In the Leiden 85-Plus study, subjects who developed diabetes and had more than three features of the MetS had lower levels of lipopolysaccharide (LPS)-stimulated whole blood release of IL-10 than those who did not. 22 In another study, Esposito et al. 23 examined the relationship of IL-10 to the MetS in obese women. As a group, obese women had higher circulating levels of IL-6, CRP, and IL-10 than non-obese women. In both obese and non-obese women, IL-10 levels were lower in those with than in those without the MetS. These results show that circulating levels of the anti-inflammatory cytokine IL-10 are elevated in obese women and that low IL-10 levels are associated with the MetS.
C-reactive Protein and the Metabolic Syndrome
The best characterized and standardized marker and mediator of inflammation and a predictor of future CVEs is CRP. 24 Numerous studies have now confirmed that CRP levels are elevated in subjects with the MetS. Yudkin et al. 25 conducted Z-score analyses in 107 patients without diabetes and The largest study to date that examined the association between inflammation and the MetS was the third NHANES study. 27 In a representative sample of the US population (8,570 participants >20 years of age), subjects with the MetS, defined using ATP-III criteria, were more likely than those without the syndrome to have elevated levels of markers of inflammation such as CRP, fibrinogen, and leukocyte count. Thus, there appears to be a clear relationship between the number of metabolic features and increasing hsCRP levels. In addition, we have shown that CRP levels were equivalent to the ratio of high-molecular-weight (HMW) adiponectin-CRP in predicting MetS using receptor-operated curve (ROC) analyses. 28 Furthermore, Sugiura et al. 29 have also reported that leptin (positively) and adiponectin (negatively)
were independently associated with CRP. Thus, MetS is a pro-inflammatory state characterized by increased CRP levels.
Elevated High-sensitivity C-reactive Protein Levels Predict Increased Cardiovascular Risk in Metabolic Syndrome
Evidence supporting the hypothesis that elevated CRP levels contribute to increased CV risk is now available from at least six major prospective studies, proposed that hsCRP be added as a clinical criterion for MetS and for creation of an hsCRP-modified CHD risk score. 36 In the WOSCOPS, in which 6,447 men were followed for 4.9 years, an hsCRP level >3mg/l predicted greater CVD risk in patients with the MetS in a multivariate model. In the Framingham Offspring Study, both CRP and
MetS were independent predictors of new CV events, but were not additive.
In an Italian study, patients with MetS and CRP >3mg/l had higher incidence of both carotid and coronary artery disease. Pischon et al. showed in the Nurses' Health Study (NHS) and Health Professionals Follow-up Study (HPFS)
that while MetS was a strong predictor of CHD in both men and women, CRP was additive in men only. It should be emphasized that in this study a modified definition of MetS was used as waist circumference, blood pressure, and glucose were not available at baseline. In a smaller Japanese study of 461 patients with acute myocardial infarction (AMI), CRP levels were additive to MetS in predicting future major adverse cardiac events.
Furthermore, a recent investigation relating increased CRP levels and MetS in 1,044 older individuals (≥65 years of age) has also led to the conclusion that MetS is associated with low-grade systemic inflammation; the association is mainly supported by a strong independent correlation between waist circumference and high hsCRP levels. Collectively, all of these studies support the hypothesis that an increased CRP in the setting of MetS confers an increased risk of future CV events.
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Adipokines and Metabolic Syndrome
The adipose tissue was originally considered as a storage site of excess energy as triglycerides, but several studies now indicate that it is a hormonally active system. [37] [38] [39] [40] [41] Adipose tissue is now known to express and secrete a variety of bioactive peptides, known as adipokines, which act at both the local (autocrine/paracrine) and systemic (endocrine) level and secretes a series of adipocyte-derived biologically active molecules such as IL-6, TNF, plasminogen activator inhibitor-1 (PAI-1), leptin, adiponectin, etc.
Adipose tissue excess or obesity, particularly in the visceral compartment, is associated with insulin resistance, hyperglycemia, dyslipidemia, hypertension, and pro-thrombotic and pro-inflammatory states.
Adiponectin
One of the most widely studied secreted adipokines is adiponectin.
Adiponectin is an important link between adiposity, type 2 diabetes, and CVD. Circulating adiponectin concentrations are reduced in humans with obesity, type 2 diabetes, and CAD. Adiponectin-deficient mice exhibit dietinduced insulin resistance. In humans, low plasma adiponectin concentrations independently predict the development of type 2 diabetes and MI. Hypoadiponectinemia is also associated with MetS. Furthermore, adiponectin concentrations have been found in a number of studies to be inversely associated with systemic inflammation, as evidenced by increased concentrations of hsCRP. [42] [43] [44] [45] [46] [47] In the circulation, adiponectin is found in three major forms: as trimers (low In an eight-year prospective follow-up of 14,719 women in the Women's Health
Study, a high-sensitivity C-reactive protein level >3mg/l in patients with the metabolic syndrome predicted a greater age-adjusted relative risk for future cardiovascular events.
We evaluated whether hsCRP, adiponectin, or the ratio of adiponectin or its oligomers especially the HMW oligomer with hsCRP predict MetS in subjects with MetS compared with healthy controls. 28, 52 One hundred and twenty-three subjects with MetS and 91 healthy controls were studied.
MetS subjects had significantly higher hsCRP and lower total adiponectin and its oligomers relative to controls (p<0.0001). The ratio of HMW-total adiponectin and the adiponectin-CRP ratio was significantly lower in
MetS subjects compared with controls (p<0.005). The odds ratio (OR)
of MetS using the 75th percentile cut-off of CRP was 3.8 (95% confidence interval [CI] 2.1-6.8) and equivalent to either low total adiponectin (OR 2.5, 95% CI 1.3-4.5), its oligomers or the adiponectin-hsCRP ratio (OR 2.6, 95% CI 1.5-4.8). Thus, measurements of CRP, adiponectin, or its oligomers provide robust biomarkers for predicting MetS.
Several mechanisms for adiponectin's metabolic effects have been described. [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] In the liver, adiponectin enhances insulin sensitivity, Taken together, these studies suggest that adiponectin is a unique adipocyte-derived hormone with antidiabetic, anti-inflammatory, and anti-atherogenic effects.
Leptin
Leptin is a 16kDa polypeptide containing 167 amino acids with structural homology to cytokines. [53] [54] [55] [56] [57] Adipocytes secrete leptin in direct proportion to adipose tissue mass as well as nutritional status, and this secretion is greater from subcutaneous relative to visceral adipose tissue. [53] [54] [55] [56] [57] Leptin expression and secretion are also regulated by a variety of other factors.
For example, leptin is increased by insulin, glucocorticoids, TNF, estrogens, and cytidine-cytidine-adenosine-adenosine-thymidine (CCAAT)/enhancerbinding protein, and decreased by β3-adrenergic activity, androgens, free fatty acids, growth hormone (GH), and peroxisome proliferator-activated receptor agonists. [53] [54] [55] [56] [57] Obesity is known to be associated with hyperleptinemia, reflecting resistance to leptin because obese subjects remain overweight despite the high circulating levels of leptin. Neither endogenously high leptin levels nor treatment with exogenous leptin is effective in ameliorating this obesity, consistent with a state of leptin resistance. [53] [54] [55] [56] [57] In a major prospective cohort (WOSCOPS), serum leptin levels have been independently associated with CHD. 58 In addition, leptin levels independently predict future cardiovascular events in subjects with established angiographic coronary lesions.
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With regard to leptin in MetS, in a prospective population-based survey examining 888 subjects 40-79 years of age, subjects were identified fulfilling the WHO and the National Cholesterol Education Program-ATP-III (NCEP-ATP-III) criteria for diagnosing the MetS and had higher levels of leptin compared with matched controls.
Resistin
Another adipocyte-derived cytokine that has been recently isolated is resistin, and it has been suggested that this protein impairs glucose tolerance. [59] [60] [61] Circulating resistin levels are increased in mouse models of obesity and in obese humans, are decreased by the antidiabetic drug rosiglitazone, and are increased in diet-induced and genetic forms of obesity, and administration of antiresistin antibody has been shown to improve blood sugar and insulin action in mice with diet-induced obesity. [59] [60] [61] Similarly, resistin has been implicated in the pathogenesis of diabetic complications and diabetes. [58] [59] [60] The source of resistin is now under dispute as it may not come directly from the adipocytes, and may rather originate from inflammatory cells (macrophages) infiltrating the fat tissue. However, numerous epidemiological studies in humans have failed to provide a clear and consistent link between resistin expression in adipose tissue or circulating resistin levels and adiposity or insulin resistance. [59] [60] [61] Much further research is needed to determine the role of resistin in the MetS in humans.
Retinol-binding Protein 4
Recently, retinol-binding protein 4 (RBP4) was identified as a novel adipokine that is increased in different animal models of insulin resistance. [62] [63] [64] It increases hepatic expression of the gluconeogenic enzyme, phosphoenolpyruvate carboxykinase (PEPCK), and impairs insulin signaling and action in skeletal muscle. Furthermore, circulating serum levels of RBP4 in man correlate inversely with insulin sensitivity measured with the euglycemic-hyperinsulinemic clamp technique. [62] [63] [64] It is elevated not only in subjects with obesity, type 2 diabetes, and IGT, but also in normoglycemic and insulin-resistant subjects with a strong family history of type 2 diabetes and in subjects with the MetS; however, the relationship is not always consistent across studies. [62] [63] [64] [65] Therefore, among the adipokines, low levels of adiponectin are associated with MetS; however, more studies need to be performed to evaluate the role of leptin and resistin in the MetS.
Monocyte Chemoattractant Protein-1
Monocyte 
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Inhibition of CCR2 has been shown to improve obesity and type 2 diabetes by interfering with macrophage infiltration of the adipose tissue and decreasing resultant inflammation.
Serum Amyloid A
Serum amyloid A (SAA) is an acute-phase reactant whose level in the blood increases in response to various insults. It is expressed in the liver, but its physiological role is not well understood. In the Cholesterol and Recurrent Events (CARE) study, Ridker et al. 69 showed that levels of CRP and SAA after MI were independently associated with increased risk for recurrent coronary events. Increased levels of SAA have been reported in patients with type 2 diabetes and with IGT, and Pickup et al. 15 have shown that, like CRP, SAA levels increase with an increase in the number of features of the MetS. Insulin resistance and adiposity correlate to increased levels of SAA in subjects with type 2 diabetes. 70 Thus, emerging evidence points to increased SAA levels as an additional marker of inflammation in the MetS; however, this needs to be confirmed in future studies.
Plasminogen Activator Inhibitor-1 and the
Metabolic Syndrome
Population studies of people without diabetes have shown that features of the MetS cluster with coagulation and fibrinolytic proteins. PAI-1 is a member of the serine protease inhibitor family and is the primary inhibitor of fibrinolysis by inactivating urokinase-type and tissue-type plasminogen activator. The hemostatic abnormality that has been most consistently associated with insulin resistance is an elevated PAI-1 level. 
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The mature adipocyte is an important source of circulating PAI-1 in humans. Severely obese adults have two-fold higher adipose tissue PAI-1 mRNA levels and seven-fold higher plasma PAI-1 protein levels than observed in lean adults. [71] [72] [73] [74] [75] [76] [77] Thus, PAI-1 may contribute to the development of obesity and insulin resistance and may be a causal link between obesity and CVD.
In summary, the MetS is a pro-inflammatory state as evidenced by increased levels of IL-6, TNF as well as CRP, SAA and leptin, PAI-1, and lower levels of adiponectin and IL-10 (see Table 1 ), and that each of the features of the MetS in effect contribute to this pro-inflammatory state.
While CRP levels are strongly related to both insulin resistance and adiposity, currently it is difficult to conclude whether low-grade inflammation induces insulin resistance and the MetS or is a consequence. A reasonable proposal is that an imbalance in favor of proinflammatory cytokines from adipose tissue (hypoadiponectinemia and increased IL-6) and other sources triggers CRP secretion. In turn, this can exacerbate mild insulin resistance and result in accentuation of other metabolic abnormalities that constitute the MetS.
Oxidative Stress and Metabolic Syndrome
Oxidative stress may be defined as an imbalance between production and degradation of reactive oxygen species (ROS). Several lines of evidence point to the role of increased oxidative stress in CVD. In fact, diabetes is a pro-oxidant state characterized by increased LDL oxidation, increased monocyte superoxide, increased nitrotyrosine, and urinary F2-isoprostanes.
Several lines of evidence indicate that MetS may be a pro-oxidant state [78] [79] [80] [81] (see Table 2 ). The levels of lipid peroxidation products, carbonylated proteins, nicotinamide adenine dinucleotide phosphate (NADPH)-oxidases (NOXs), and catalase activity were found to be high, while reduced glutathione (GSH) levels were observed in MetS patients compared with healthy controls. [78] [79] [80] [81] Oxidative stress, mainly superoxide, plays a critical role as well as oral hyperglycemics (21%).
A diet rich in fats also produces a state of oxidative stress. Fat-overloaded patients with MetS also showed an increase in lipid peroxidation products, carbonylated proteins, and GSH and a reduction in NOX and catalase activity in comparison with healthy controls. It was also shown that fat overload increases total glutathione and GSH levels, indicating that the antioxidative system is trying to neutralize the oxidative stress but is overwhelmed. [78] [79] [80] [81] NOXs are electron transporter enzymes that catalyze the production of superoxide from oxygen, which is the precursor of other ROS. In mammals, six NOX homologues have been identified. [78] [79] [80] [81] Most mammalian cells express at least one NOX. Activity and expression of NOX2 in phagocytic cells was found to be increased in subjects with MetS. [78] [79] [80] [81] MetS patients also showed increased levels of nitrotyrosine. The reaction of superoxide with nitrous oxide leads to production of peroxynitrite, a powerful oxidant molecule. The association of NOX overactivity with high nitrotyrosine levels suggests the possibility that phagocytic NOX may be involved in endothelial dysfunction in MetS. [78] [79] [80] [81] Furthermore, patients with MetS were found to have a lower concentration of markers of NO formation, which included whole blood nitrite, plasma nitrite, and cyclic guanosine monophosphate (cGMP).
78-81
Conclusion
Emerging laboratory and clinical evidence have proved that there is a strong relationship between inflammation, especially high levels of CRP and PAI-1, low levels of adiponectin, and measures of oxidative stress and various features of MetS. The evaluation of biomarkers of inflammation and oxidative stress in MetS may help identify subjects at high risk for future diabetes and CVD. ■
